Masonic Cancer Center, University of Minnesota
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Masonic Cancer Center, University of Minnesota sits in the top decile of US sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count).
Masonic Cancer Center, University of Minnesota: 249 sponsored US clinical trials, 36 recruiting.
Masonic Cancer Center, University of Minnesota sponsors 249 registered US clinical trials on ClinicalTrials.gov, 36 of them currently recruiting, and 127 completed. 1 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 7 trials.
Top-decile sponsor footprint
Masonic Cancer Center, University of Minnesota ranks in the top decile of sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 201 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
249 total, page 2 of 5
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
NCT05123040
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT05708924
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
NCT05809557
QuitGuide for American Indians: Aims 2 & 3
NCT05447156
App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
NCT05502302
HCW9218 in Select Advanced Solid Tumors
NCT05322408
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
NCT05120570
Sugars in Cigarettes
NCT05308316
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
NCT04714372
Telehealth-Filter Ventilation ( COMET2P1 )
NCT04969783
Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy
NCT04858594
Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices
NCT04740008
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
NCT04630769
Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
NCT03978117
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NCT04555811
Metabolism of NNK in Japanese Americans
NCT04228952
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
NCT04466098
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
NCT04363346
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
NCT04055844
A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers
NCT04204772
A Study of FMT in Patients With AML Allo HSCT in Recipients
NCT03678493
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
NCT03981705
Radiation and Combination Immunotherapy for Melanoma
NCT03850691
Trial of Indole-3-Carbinol and Silibinin
NCT03687073
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
NCT03383055
COMET2 Project 1 Filter Ventilation Study
NCT03637972
Exemestane in Post-Menopausal Women With NSCLC
NCT02666105
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
NCT03557749
Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training
NCT03609203
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
NCT03417154
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
NCT03367546
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
NCT03294304
Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy
NCT03728699
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
NCT04225572
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
NCT03213964
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
NCT03019666
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
NCT03054909
Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction
NCT03316456
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
NCT03050216
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT02722668
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
NCT03081780
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
NCT02989844
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
NCT02988843
Allo HSCT Using RIC for Hematological Diseases
NCT02661035
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
NCT02991898
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
NCT02988466
Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism
NCT02999399
Study of Cellutome System for Treatment of Individual Lesions in EB Pts
NCT02670837
Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
NCT02525029
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
NCT02582775
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 76 |
| Phase 2 | 107 |
| Phase 3 | 1 |
What is open in the Masonic Cancer Center, University of Minnesota pipeline
36 recruiting of 249 indexed (14% open); 127 completed (51%).
Phase mix: 1 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Masonic Cancer Center, University of Minnesota: open-pipeline peers nationwide
Peers matched on 249 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 249 trials (± recruiting share)
- University of South Florida · 252 trials · 17% recruiting
- Boston Medical Center · 253 trials · 11% recruiting
- Shire · 245 trials · 0% recruiting
- University of Cincinnati · 245 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- ModernaTX · 14% recruiting · 90 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this Masonic Cancer Center, University of Minnesota page
249 registered trials is a research-attention snapshot, not an endorsement of Masonic Cancer Center, University of Minnesota or any single study.
- 36 of Masonic Cancer Center, University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Masonic Cancer Center, University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Masonic Cancer Center, University of Minnesota pipeline card: 249 registered trials from official public datasets.Report a data error.